702 related articles for article (PubMed ID: 27138015)
1. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
Crawford J; Prado CM; Johnston MA; Gralla RJ; Taylor RP; Hancock ML; Dalton JT
Curr Oncol Rep; 2016 Jun; 18(6):37. PubMed ID: 27138015
[TBL] [Abstract][Full Text] [Related]
2. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.
Dalton JT; Taylor RP; Mohler ML; Steiner MS
Curr Opin Support Palliat Care; 2013 Dec; 7(4):345-51. PubMed ID: 24189892
[TBL] [Abstract][Full Text] [Related]
3. Enobosarm (GTx-024, S-22): a potential treatment for cachexia.
Srinath R; Dobs A
Future Oncol; 2014 Feb; 10(2):187-94. PubMed ID: 24490605
[TBL] [Abstract][Full Text] [Related]
4. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.
Dobs AS; Boccia RV; Croot CC; Gabrail NY; Dalton JT; Hancock ML; Johnston MA; Steiner MS
Lancet Oncol; 2013 Apr; 14(4):335-45. PubMed ID: 23499390
[TBL] [Abstract][Full Text] [Related]
5. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.
Dalton JT; Barnette KG; Bohl CE; Hancock ML; Rodriguez D; Dodson ST; Morton RA; Steiner MS
J Cachexia Sarcopenia Muscle; 2011 Sep; 2(3):153-161. PubMed ID: 22031847
[TBL] [Abstract][Full Text] [Related]
6. Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy.
Kinsey E; Ajazi E; Wang X; Johnston MAM; Crawford J
J Thorac Oncol; 2018 Sep; 13(9):1294-1301. PubMed ID: 29981438
[TBL] [Abstract][Full Text] [Related]
7. The relationship between muscle mass and function in cancer cachexia: smoke and mirrors?
Ramage MI; Skipworth RJE
Curr Opin Support Palliat Care; 2018 Dec; 12(4):439-444. PubMed ID: 30138131
[TBL] [Abstract][Full Text] [Related]
8. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
Katakami N; Uchino J; Yokoyama T; Naito T; Kondo M; Yamada K; Kitajima H; Yoshimori K; Sato K; Saito H; Aoe K; Tsuji T; Takiguchi Y; Takayama K; Komura N; Takiguchi T; Eguchi K
Cancer; 2018 Feb; 124(3):606-616. PubMed ID: 29205286
[TBL] [Abstract][Full Text] [Related]
9. Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia.
Zilbermint MF; Dobs AS
Future Oncol; 2009 Oct; 5(8):1211-20. PubMed ID: 19852734
[TBL] [Abstract][Full Text] [Related]
10. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
Garcia JM; Boccia RV; Graham CD; Yan Y; Duus EM; Allen S; Friend J
Lancet Oncol; 2015 Jan; 16(1):108-16. PubMed ID: 25524795
[TBL] [Abstract][Full Text] [Related]
11. Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology.
Anker MS; von Haehling S; Springer J; Banach M; Anker SD
Int J Cardiol; 2013 Jan; 162(2):73-6. PubMed ID: 23174169
[TBL] [Abstract][Full Text] [Related]
12. Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models.
Morimoto M; Aikawa K; Hara T; Yamaoka M
Oncol Lett; 2017 Dec; 14(6):8066-8071. PubMed ID: 29344250
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic options for cachexia and sarcopenia.
Molfino A; Amabile MI; Rossi Fanelli F; Muscaritoli M
Expert Opin Biol Ther; 2016 Oct; 16(10):1239-44. PubMed ID: 27382931
[TBL] [Abstract][Full Text] [Related]
14. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.
Solomon ZJ; Mirabal JR; Mazur DJ; Kohn TP; Lipshultz LI; Pastuszak AW
Sex Med Rev; 2019 Jan; 7(1):84-94. PubMed ID: 30503797
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design.
Groarke JD; Crawford J; Collins SM; Lubaczewski SL; Breen DM; Harrington MA; Jacobs I; Qiu R; Revkin J; Rossulek MI; Saxena AR
J Cachexia Sarcopenia Muscle; 2024 Jun; 15(3):1054-1061. PubMed ID: 38500292
[TBL] [Abstract][Full Text] [Related]
16. Clinical results in cachexia therapeutics.
Crawford J
Curr Opin Clin Nutr Metab Care; 2016 May; 19(3):199-204. PubMed ID: 26974316
[TBL] [Abstract][Full Text] [Related]
17. Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials.
Fonseca GWPD; Dworatzek E; Ebner N; Von Haehling S
Expert Opin Investig Drugs; 2020 Aug; 29(8):881-891. PubMed ID: 32476495
[TBL] [Abstract][Full Text] [Related]
18. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.
Takayama K; Katakami N; Yokoyama T; Atagi S; Yoshimori K; Kagamu H; Saito H; Takiguchi Y; Aoe K; Koyama A; Komura N; Eguchi K
Support Care Cancer; 2016 Aug; 24(8):3495-505. PubMed ID: 27005463
[TBL] [Abstract][Full Text] [Related]
19. Enobosarm (GTx-024) Modulates Adult Skeletal Muscle Mass Independently of the Androgen Receptor in the Satellite Cell Lineage.
Dubois V; Simitsidellis I; Laurent MR; Jardi F; Saunders PT; Vanderschueren D; Claessens F
Endocrinology; 2015 Dec; 156(12):4522-33. PubMed ID: 26393303
[TBL] [Abstract][Full Text] [Related]
20. A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia.
Papanicolaou DA; Ather SN; Zhu H; Zhou Y; Lutkiewicz J; Scott BB; Chandler J
J Nutr Health Aging; 2013; 17(6):533-43. PubMed ID: 23732550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
